IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.892
Totale 2.892
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.892
Totale 2.892
Salva come PNG Salva come JPEG
Città #
Genova 1.898
Rapallo 518
Genoa 453
Bordighera 23
Totale 2.892
Salva come PNG Salva come JPEG
Nome #
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 168
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 141
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 136
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 131
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 127
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 124
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 124
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 123
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 119
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 114
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 105
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 100
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 99
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 86
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 82
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 81
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 81
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 72
Solar radiation as a risk factor for cutaneous melanoma: Review 69
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 66
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 63
Current State of Target Treatment in BRAF Mutated Melanoma 63
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 60
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 59
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 54
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 51
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 50
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 46
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 46
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 35
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 35
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 32
How to make immunotherapy an effective therapeutic choice for uveal melanoma 31
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 23
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 22
How I perform fertility preservation in breast cancer patients 20
Molecular Assessment in Patients with Melanoma: When and Why? 18
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 17
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 16
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 16
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 11
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 9
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 9
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 8
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 8
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 8
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 7
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 7
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 6
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 6
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib 6
Sun exposure and melanoma prognostic factors 5
Uveal melanoma 5
Upcoming strategies for the treatment of metastatic melanoma 5
mAbs targeting CTLA-4 and clinical outcomes 4
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 4
Uveal melanoma 4
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 4
Primary endobronchial melanoma: a case report and clinical management indications 4
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 4
Management of immune-related adverse events during treatment with immune checkpoint inhibitors 4
Treatment of metastatic uveal melanoma with intravenous fotemustine 3
Update on Metastatic Uveal Melanoma: Progress and Challenges 2
BRAF-mutant melanoma: Treatment approaches, resistance mechanisms, and diagnostic strategies 2
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 2
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy 2
Totale 3.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.905
article - articoli 11.410
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 239
Totale 23.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019116 0 0 0 0 0 0 0 0 0 21 50 45
2019/2020644 25 17 16 37 44 71 104 54 72 102 83 19
2020/2021358 22 23 29 46 31 14 27 35 31 48 35 17
2021/2022434 21 21 23 46 21 42 19 81 38 61 13 48
2022/2023628 49 52 6 53 112 96 4 48 92 8 100 8
2023/2024411 12 43 18 82 35 84 23 57 30 27 0 0
Totale 3.044